BCL2 and acute myeloid leukemia: It has been proposed that the evaluation of BCL2 levels at AML diagnosis by mRNA quantification or immunohistochemistry, could serve as a biomarker predicting the response to VEN or anti-BCL2 treatment, because elevated BCL2 protein levels correlate with higher sensitivities to VEN (38).